Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
+ 1147 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- The Kirklin Clinic at Acton Road — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
+ 467 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Locations: - Local Institution - 007-556-A — Goodyear, Arizona
- USOR - Arizona Oncology - Prescott Valley — Prescott Valley, Arizona
- Local Institution - 007-568-A — Safford, Arizona
+ 217 more sites in the U.S.
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Locations: - Pioneer Research Center — Bullhead City, Arizona
- Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
+ 181 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Locations: - Clearview Cancer Institute — Huntsville, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Banner University Medical Center Phoenix — Phoenix, Arizona
+ 88 more sites in the U.S.
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Locations: - Clinical Study Site — Chandler, Arizona
- Clinical Study Site — Phoenix, Arizona
- Clinical Study Site — Hot Springs, Arkansas
+ 86 more sites in the U.S.
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Locations: - Clearview Cancer Institute — Huntsville, Alabama
- Infirmary Cancer Care — Mobile, Alabama
- City of Hope, Phoenix — Phoenix, Arizona
+ 82 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Locations: - Banner University Medical Center — Phoenix, Arizona
- TMC Healthcare — Tucson, Arizona
- Genesis Cancer and Blood Institute — Hot Springs, Arkansas
+ 73 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- UC San Diego Health System - Encinitas — Encinitas, California
+ 55 more sites in the U.S.
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Locations: - Local Institution - 0347 — Birmingham, Alabama
- Local Institution - 0686 — Springdale, Arkansas
- Local Institution - 0581 — Fullerton, California
+ 51 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Locations: - Banner MD Anderson Cancer Center ( Site 0181) — Gilbert, Arizona
- The University of Arizona Cancer Center - North Campus ( Site 0163) — Tucson, Arizona
- Providence St. Jude Medical Center ( Site 0106) — Fullerton, California
+ 45 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Locations: - Local Institution - 0487 — Mobile, Alabama
- Southern Arizona VA Health Care System — Tucson, Arizona
- Local Institution - 0112 — Los Angeles, California
+ 42 more sites in the U.S.